A methodological appraisal of recent real-world data publications on dabigatran

JAMA Internal Medicine

Volumn 175, Issue 7, 2015, Pages 1244-

  Zint, Kristina ^a   Kreuzer, Jörg ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN ETEXILATE; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE;

ANTICOAGULANT THERAPY; ATRIAL FIBRILLATION; BLEEDING; HUMAN; LETTER; MEDICARE; PRIORITY JOURNAL; PUBLICATION; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; FEMALE; MALE;

ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; FEMALE; HEMORRHAGE; HUMANS; MALE; WARFARIN;

EID: 84937510661     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2015.1280     Document Type: Letter

References (4)

1. Hernandez I, Baik SH, Pi?era A, Zhang Y. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med. 2015;175(1):18-24.
2. Graham DJ, Reichman ME,WerneckeM, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for non-valvular atrial fibrillation. Circulation. 2015;131(2):157-164.
3. US FDA Drug Safety Communication. FDA study of Medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM397606.pdf. Accessed November 11, 2014.
4. Kurth T,Walker AM, Glynn RJ, et al. Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol. 2006;163 (3):262-270.